News About: Pharm. Industry
20 Merck executives to visit Korea
Some 20 executives of the U.S. pharmaceutical firm Merck & Co. are scheduled to visit Seoul to attend Bio Korea 2007 in Seoul, Korea from September 1214, 2007 at COEX.
Bio Korea 2007 will feature high-level confere...
Roche Diagnostics Korea to introduce CoaguChek XS systemRoche Diagnostics Korea is preparing to sell the CoaguChek XS system under the health insurance coverage after its approval from the Korea Food and Drug Administration, accordin...
|
'M-vix' to debut in October
SK Chemicals said on September 3 that the company is planning to begin selling its anti-impotence medication M-vix (mirodenafil HCl) in October as the Korea Food and Drug Administration plans to enact a bill to design...
Eli Lilly to expand R&D investment
Eli Lilly and Co. will unveil its plans to increase investment for cancer research in Korea, aiming to take advantage of the country's talented medical scientists and need for new drugs, according to Lilly Korea.
L...
Dong-A to showcase one-touch package of Panpyrin Q
Dong-A Pharmaceutical Co. is preparing to introduce the comfort of one-touch package containing five bottle of Panpyrin Q, an oral OTC cold remedy from this month.
As for the new package, consumers will find it eas...
Prices of imported drug raw materials soar
Prices of imported raw materials such as intermediate have been soaring, worrying the domestic importers and manufacturers for finished products.
The majority of Chinese drug bulk manufacturers have raised their ex...
Ildong's CP rated 'A3+'
Korea Ratings Corporation said on September 2 it has assigned a 'A3+' to Ildong Pharm's commercial paper.
KR said Ildong's solid sales performance of flagship items is considered the best competitiveness of the co...
Drug company employment plans showing no increases in 2nd half of 2007.
Along with overall economic recession the pharmaceutical industry showed about 10% down in the employment plan, while the top 10 companies may keep usual levels as previous years according to Yakup Press survey based ...
Dong-A to enter "sibutramine" anti-obesity drug marketsDong-A is going to launch Shranker capsule (sibutramine), an anti-obesity drug, into the markets. Shranker means a "shrink" in German, implying the reduction of a wait size and ...
|
VGX, Biokinetics forge partnership
VGX International announced on August 31 that it has inked a memorandum of understanding (MOU) with Biokinetics Inc., US centered professional engineering services company, to strengthen its cGMP consulting business i...
